[Form 4] Medtronic plc Insider Trading Activity

Rhea-AI Filing Summary

Pegasystems Inc. (PEGA) has filed a Form 144 indicating that insider Kenneth Stillwell plans to sell 11,147 common shares via Morgan Stanley Smith Barney on or after 4 Aug 2025. The shares have an aggregate market value of $648,670.68 and equal roughly 0.007 % of the 171,080,665 shares outstanding. The stock will be sold on NASDAQ and originates from an option exercise executed the same day.

The filing also discloses prior sales by the same insider during the last three months: 4,000 shares on 1 Aug 2025 ($230,847), 4,000 shares on 1 Jul 2025 ($210,564), and 2,000 shares on 2 Jun 2025 ($194,960), for total proceeds of about $636,371. The signer affirms no knowledge of undisclosed adverse information.

No operational, financial, or strategic updates accompany the notice; it serves solely to comply with Rule 144 requirements for the contemplated secondary sale.

Positive

• Proposed sale represents only 0.007 % of shares outstanding, indicating minimal market supply impact.

Negative

• Continued insider selling totalling 21,147 shares over four months could be interpreted as reduced executive confidence.

Insights

Securities Analyst

TL;DR: 11,147-share PEGA insider sale worth $649k; size is immaterial, signals continued disposal trend, impact neutral.

The proposed sale is modest at only 0.007 % of shares outstanding and follows three smaller transactions that cumulatively moved 10,000 shares in the prior quarter. While consecutive monthly disposals can prompt sentiment questions, the volumes and dollar amounts are immaterial relative to Pegasystems’ market capitalization and trading liquidity. The shares stem from option exercise, a routine monetisation method for executives. There is no accompanying adverse disclosure, and the signer certifies the absence of undisclosed negative information. Overall, the filing is compliant housekeeping rather than a catalyst. Market impact should be limited barring broader insider-selling patterns or coincident corporate developments.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wall Brett A.

(Last) (First) (Middle)

710 MEDTRONIC PARKWAY

(Street)

MINNEAPOLIS MN 55432

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Medtronic plc [ MDT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Pres Neuroscience

3. Date of Earliest Transaction (Month/Day/Year)
08/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	08/01/2025		M		15,249(1)	A	$0	66,531	D
Ordinary Shares	08/01/2025		F		7,744(2)	D	$89.34	58,787	D
Ordinary Shares	08/01/2025		F		3,850(3)	D	$89.34	54,937	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Share Units	(4)	08/01/2025		M			15,249	(5)	(5)	Performance Share Unit	15,249	$0	0	D

Explanation of Responses:

1. Represents shares issued upon the settlement of performance-vesting restricted stock units granted on August 1, 2022 and earned dividend equivalents.

2. Represents shares withheld for taxes upon the settlement of performance-vesting restricted stock units that vested on August 1, 2025.

3. Represents shares withheld for payment of taxes upon the vesting of restricted stock units previously reported on Table I.

4. Each performance share unit represents a contingent right to receive one share of Medtronic common stock.

5. The performance share units vested on August 1, 2025.

Remarks:

	/s/ Patricia Walesiewicz, attorney-in-fact	08/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Pegasystems (PEGA) shares are being offered in the Form 144 filing?

11,147 common shares are slated for sale.

What is the estimated market value of the proposed PEGA share sale?

The filing cites an aggregate value of $648,670.68.

Which insider is selling and which broker will handle the transaction?

Insider Kenneth Stillwell plans to sell through Morgan Stanley Smith Barney LLC.

When is the approximate sale date for these Pegasystems shares?

The shares may be sold on or about 4 August 2025.

How many PEGA shares has the insider sold in the past three months?

The insider sold 10,000 shares for total proceeds of about $636,371.

What portion of Pegasystems’ shares outstanding does the planned sale represent?

Roughly 0.007 % of the 171,080,665 shares outstanding.